BIOCRYST PHARMACEUTICALS, INC.
In the published model solve dated 2026-Q2, anchored at $9.57, BIOCRYST PHARMACEUTICALS, INC. (BCRX) is priced for +14.9% growth. boothcheck publishes no house fair value, target price, or buy/sell rating; individual model outputs and user-controlled scenarios are analytical inputs, not Boothcheck targets. The narrative was composed July 25, 2026 from SEC EDGAR filings.
• ORLADEYO is the whole company today, and management has guided global net revenue from it to between $625 million and $645 million for 2026, with total revenue of $635 million to $660 million [Source: BioCryst first quarter 2026 results, reported May 6, 2026]. • The economics of that revenue are the reason the stock is not cheap on any conventional measure: gross margin runs about 91.3%, and today's price holds a steady-state operating margin of about 36.5% as its central assumption, a level n
Is BCRX overvalued? See what's priced in →
289 institutional managers reported holding BCRX in 13F filings for the quarter ended 2026-03-31. 63 opened new positions that quarter. Held by Vanguard Group, BlackRock, State Street, among others. On the short side, 40.6M shares were sold short as of the 2026-06-15 count, about 17% of shares outstanding (11.4 days of typical volume to cover).
Quarterly 13F filings arrive up to 45 days after quarter end, so the picture is never current (filed through 2026-05-29). Nothing here is investment advice.
BCRX's share count grew 36% over the past five years. It pays no dividend.
Share counts are split-adjusted; repurchase totals are gross of share issuance. Nothing here is investment advice.
Open-market insider buys at BCRX over the trailing three years: 2024: 10 buys totaling $1.05M. 16 officers and directors are on file.
Code P open-market purchases from SEC Form 4 filings, non-derivative, excluding scheduled 10b5-1 plans. Nothing here is investment advice.
BCRX's recent reports: the day-one move, then what the following quarter actually did.
| report | day one | next quarter |
|---|---|---|
| 2023-05-09 | +14.9% | -16.2% |
| 2023-08-08 | +9.3% | -8.8% |
| 2023-11-09 | +7.1% | +29.1% |
| 2024-02-28 | +2.8% | -20.0% |
Day-one is the close-to-close move around the filing. Nothing here is investment advice.
BCRX's latest 8-K filings: 2026-06-29 (items 2.05, 7.01, 9.01); 2026-06-12 (items 5.02, 5.07, 9.01); 2026-05-06 (items 2.02, 7.01, 9.01); 2026-05-04 (items 7.01, 9.01); 2026-02-26 (items 2.02, 7.01, 9.01).
Item codes are the SEC's own classification of what each report discloses. Dates link to the filing on EDGAR. Nothing here is investment advice.
Model solve date: 2026-Q2
Narrative composed: July 25, 2026
Each week boothcheck ranks the stocks whose prices are betting on the most. Read the most stretched bets archive →
boothcheck is also on Android. Get the app on Google Play →
For informational and research purposes only. Not investment advice. Not a recommendation to buy, sell, or hold any security. boothcheck is not a registered investment adviser. Past performance does not guarantee future results.